Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire Elaprase Review Extended

This article was originally published in The Pink Sheet Daily

Executive Summary

Shire's Hunter syndrome therapy Elaprase (idursulfase) has a new user fee date of Aug. 24, the company said May 17

You may also be interested in...



Shire’s Elaprase Approved For Hunter Syndrome

The company plans to launch the orphan enzyme replacement therapy within 30 days.

Shire’s Elaprase Approved For Hunter Syndrome

The company plans to launch the orphan enzyme replacement therapy within 30 days.

Shire Submits Elaprase BLA For Hunter Syndrome

Orphan therapy would be first human enzyme replacement therapy for the genetic disorder.

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel